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Introduction
For many years it has been recognised that radiographic
density of the breast tissues on the mammogram is asso-
ciated with the risk of developing cancer, and that women
with the densest pattern have a 4–6 times relative risk of
breast cancer compared with women with the most lucent
pattern. Recently the huge potential of this observation for
detecting and monitoring risk has been recognised, and is
enabled by the implementation of routine mammographic
screening of the normal population and those at increased
risk in whom screening can start from as young as
30 years. The cellular basis for the differences between
individuals has never been fully explained. There has been
no firm evidence for the quasi-pathological descriptions
used. The paper by Alowami and colleagues in this issue
provides an interesting clue, supported by data, for the
stroma and its proteins as determinant factors in this
radiographic density on the mammogram [1].
Breast density as a biomarker of risk
Wolfe first described a means of categorising the appear-
ances of breast tissue on the mammogram and showed
that the densest patterns were associated with an
increased risk of developing breast cancer when compared
with mammograms showing chiefly fatty appearances [2].
For years this was debated and doubted in the literature,
but in the late 1990s many observers confirmed this rela-
tionship conclusively, and the risk–density relationships
were explored in high-quality epidemiological studies. This
literature has recently been comprehensively reviewed by
Heine [3,4] and appraised by Byrne [5] for the way in
which it reveals an understanding of breast cancer.
One of the commonest reasons for having an increased
risk of breast cancer is family history, and a recent study of
twins has demonstrated that about 60% of the density can
be accounted for by heritable factors, the remaining
proportion lying in lifestyle and mutable factors [6].
Density has been shown to be associated with the lifestyle
risk factors known for breast cancer such as late age at
first birth, and nulliparity [7]. It is also increased in women
on hormone replacement therapy (HRT) [7] and
decreased in women on tamoxifen [8]. It has been associ-
ated with dietary constituents believed to be associated
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Abstract
Mammographic density is recognised as a useful phenotypic biomarker of breast cancer risk. Deeper
understanding is needed of the cellular basis, but evidence is limited because of difficulty in
designing studies to validate hypotheses. The ductal epithelial components do not adequately explain
the physical and dynamic features observed. The stroma is thought to interact with ductal structures
in cancer initiation. Stromal tissues might account for the mammographic features, and this interplay
can be hypothesised to relate risk to density. In a paper in this issue of Breast Cancer Research,
Alowami has shown a relationship between density and stromal proteins, which might provide useful
insight into mammographic density.
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with breast cancer causation [9]. The two major risk
factors for breast cancer that are inversely related to
breast density are raised body mass index [10] and age
[11], both of which give rise to more fatty breasts.
When the nature of the tumours associated with higher
risk patterns on mammography is examined, they are
more likely to be grade 3 tumours, with nodes positive, of
large size and with ductal carcinoma in situ; this is inde-
pendent of the masking effect of dense glandular tissue
on mammographic diagnosis [12,13]. Change in density
occurs with time, diminishing with advancing age, but
increasing on HRT. This change can be measured, and
might be a method of monitoring the effects of interven-
tion on individual risk [14] – as for example with chemo-
prevention. Does change in density actually denote
change in risk? This link has not yet been made in the
published evidence available.
Knowledge of the cellular basis for
mammographic density
What, then, is known of the cellular basis for these obser-
vations? The literature on this is much smaller, and the
question is curiously difficult to answer. There are limita-
tions on all available methods, which introduce different
biases. Some workers have looked at autopsy material
and have been able to examine the relationship between
dense patterns and evidence of, for example, proliferative
fibrocystic change [15]. In this situation, although detailed
and accurate pathological examination can be performed,
the mammography is suboptimal because it is on a post-
mortem mastectomy specimen. When the problem is
tackled with a case–control study, the controls do not
have their tissue examined, whereas examination of the
cases might be biased owing to the reason for obtaining
biopsy tissue. In contrast, the mammography is from live
women with standard techniques [16]. The tissues are
rarely ‘normal’ because the two main types of specimens
examined are benign tissues from patients with cancer or
prophylactic mastectomies in high-risk women. This short-
fall might be resolved by using biopsy material from the
control population, but this raises both ethical difficulties
and technical problems in relating the biopsy site to the
mammographic feature.
The physical basis for tissue appearances on
mammography
Most studies recognise that the radiographically lucent
tissue is fat, and that the water-dense material is due to
epithelial and stromal elements. The physical methods of
measurement essentially divide the tissues into fat and
‘glandular elements’, namely tissues with the same density
as water [17]. Information gained from ultrasound and
magnetic resonance imaging [18] might be looking at the
same features, but using different physical principles. Their
relevance is therefore limited. Mammographers know well
that cancers ‘arise’ commonly in fatty tissue, and so there is
epithelial tissue present that is not seen on the mammo-
gram, but from which the cancer arises. An early (1990)
publication from Nottingham describing a case-control
study concluded that the density was related to fibrous and
adipose tissues in the interlobular stroma and bore no rela-
tionship to the epithelial parenchymal content [19].
Relationship of density to epithelial
pathologies
Nevertheless, many of the papers since then that explore
the issue have concentrated on the relationship to epithe-
lial proliferations – hyperplasia, atypical hyperplasia, carci-
noma in situ and fibrocystic change, echoing the original
name given by Wolfe to the densest pattern, ‘DY’, hinting
at ‘dysplasia’ as the origin [2]. Several authors [16,20,21]
have explored these relationships and have shown a weak
link between these epithelial abnormalities and dense pat-
terns. Despite this, it has been increasingly accepted that
epithelial proliferation is unlikely to account for the
increased mammographic density.
The stroma as a dynamic component in
breast carcinogenesis
There is recent evidence that the stroma is not inert but
that there might be an interplay between the breast epithe-
lial and stromal compartments, which have an effect on
the growth and progression of a breast tumour. Evidence
of loss of heterozygosity (LOH) has been demonstrated in
both epithelial and stromal compartments by Kurose and
colleagues [22] and others, suggesting that stromal
changes might have a crucial role in breast carcinogene-
sis. Finding of LOH in the two compartments does not
prove a causality of effect of one component over the
other; nonetheless, the data are intriguing. They fit with the
non-reductionist view that breast cancer is more than just
an abnormality of epithelial cells and that the stroma,
inflammatory cells and endothelial proliferation are an inte-
gral part of the tumour. Guo and colleagues [23] found
that increased tissue cellularity, greater amounts of colla-
gen, increased insulin-like growth factor-1 and tissue met-
alloproteinase-3 were found in tissue from dense breasts
in women under 50 years of age, and proposed a relation-
ship by which increased risk might be mediated.
Density changes with time
A feature of the density problem that must be taken into
account in any hypothesis of the underlying cellular
process is the relatively rapid changes that can occur in
breast density – for example, there is evidence of change
within the menstrual cycle [24]. Relatively rapid changes
due to hormones have also been shown [25]. Is this to be
accounted for by water retention within existing cells, or
changes in the number of cells? Further, the relationship
holds good at all ages, so findings must apply before and
after the menopause.227
Evidence from stromal proteins
Watson’s group have previously examined the stromal
proteins lumican and decorin in breast tumours and
normal tissues and have shown that they are inversely reg-
ulated in association with breast carcinogenesis [26]. This
present contribution explores these proteins and shows
them to be related to dense patterns. The authors showed
higher collagen density and extent of fibrosis but found no
significant difference in the density of ductal and lobular
units (epithelial component). This small project starts to
elucidate a hypothesis by which density might relate to
risk through an interplay between the stromal and epithe-
lial structures. This could provide a means by which
change in density might influence factors that have an
effect on the initiation and progression of a breast tumour.
Conclusion
Further work in this area might be productive in giving a
better understanding of this relationship between density
and risk. More understanding is needed if density meas-
ures are to be used to estimate individual risk and to
monitor change in a meaningful way. The expression of
significant cellular markers, stromal proteins, genetic
changes (LOH and comparative genomic hybridisation) or
expression profiles could be assessed on biopsy speci-
mens in association with the mammograms so that the
risk–density relationship can be more fully understood.
This might be an ethically justifiable tool for research or in
the risk assessment of high-risk women.
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